The Cooper (LTS:0I3I) Debt-to-Revenue : 0.74 (As of Jan. 2024)

View and export this data going back to 2018. Start your Free Trial

What is The Cooper Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

The Cooper's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $46 Mil. The Cooper's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $2,726 Mil. The Cooper's annualized Revenue for the quarter that ended in Jan. 2024 was $3,726 Mil. The Cooper's annualized Debt-to-Revenue for the quarter that ended in Jan. 2024 was 0.74.

The Cooper Debt-to-Revenue Historical Data

The historical data trend for The Cooper's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Cooper Debt-to-Revenue Chart

The Cooper Annual Data

Trend

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Debt-to-Revenue

Get a 7-Day Free Trial

0.69

0.85

0.51

0.84

0.72

The Cooper Quarterly Data
	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24
Debt-to-Revenue	Get a 7-Day Free Trial															0.75	0.70	0.69	0.74	0.72

Competitive Comparison of The Cooper's Debt-to-Revenue

For the Medical Instruments & Supplies subindustry, The Cooper's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

The Cooper's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where The Cooper's Debt-to-Revenue falls into.

The Cooper Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

The Cooper's Debt-to-Revenue for the fiscal year that ended in Oct. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(45.4	+	2523.8)	/	3593.2
	=	0.72

The Cooper's annualized Debt-to-Revenue for the quarter that ended in Jan. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(46.1	+	2726.2)	/	3726.4
	=	0.74

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Jan. 2024) Revenue data.

The Cooper Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of The Cooper's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

The Cooper (LTS:0I3I) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » The Cooper Companies Inc (LTS:0I3I) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

COO:USA COO:Mexico CP6:Germany C1OO34:Brazil

Address

6101 Bollinger Canyon Road, Suite 500, San Ramon, CA, USA, 94583

Website

https://www.coopercos.com

The Cooper Companies is one of the largest eye care companies in the U.S. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business and is composed of a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and clariti, Cooper controls roughly a quarter of the U.S. contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the U.S., and controls 17% of the U.S. IUD market.

The Cooper (LTS:0I3I) Headlines

No Headlines